个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Song Jianlin[1] * ; Xu Jianbiao[1] * ; Guo Jianhui[1] ; Shang Yun[1] ; Wang Junyu[1] ; Wang Tongmin[1,*1] ;
机构： [1]Second Department of General Surgery, The First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, Yunnan Province, China
出处：
DOI： 10.1016/j.acthis.2021.151769
ISSN：

摘要：
In the process of tumor development, the resistance of pancreatic cancer cells to gemcitabine (GEM) is mainly due to the suppression and dysregulation of apoptosis signals to a large extent. Therefore, it is very necessary to develop pro-apoptotic drugs for combined treatment of pancreatic cancer to increase the activity of GEM and improve the prognosis of pancreatic cancer.GEM-resistant PANC-1 cells were treated with increasing doses of GEM. The effects of GEM and TET on apoptosis were evaluated by flow cytometry and Hoechst 33258 staining. We also evaluated the expression of survivin by real-time PCR, and the expression levels of proteins involved in apoptosis, autophagy, and PI3K/Akt/mTOR signaling were detected by western blotting. The results showed that TET downregulated expression of survivin by inhibiting the PI3K/Akt/mTOR signaling pathway to promote pancreatic cancer cell apoptosis, thereby enhancing pancreatic cancer cell sensitivity to GEM. Moreover, TET enhanced cytotoxic and autophagy-dependent cell death by upregulating the AMPK-autophagy axis, and this effect was reversed by inhibition of AMPK.TET promotes apoptosis by inhibiting the PI3K/Akt/mTOR signaling pathway and promotes autophagy via up-regulating the AMPK signaling pathway to play an anti-tumor effect in GEM-resistant pancreatic cancer cells, which represents a new therapeutic strategy for the treatment of GEM-resistant pancreatic cancer.Copyright © 2021 Elsevier GmbH. All rights reserved.

基金：
Kunming Medical College Combined Project (Grant No.: 2017FE468(-170)) and Yunnan Health Training Special Project of High Level Talents (Grant No.: D-2017032).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 4 区 生物
小类 | 4 区 细胞生物学
最新[2023]版：
大类 | 4 区 生物学
小类 | 4 区 细胞生物学
JCR分区：
出版当年[2020]版：
Q4 CELL BIOLOGY
最新[2023]版：
Q4 CELL BIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]Second Department of General Surgery, The First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, Yunnan Province, China
共同第一作者：
通讯作者：
通讯机构： [1]Second Department of General Surgery, The First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, Yunnan Province, China [*1]Second Department of General Surgery, The First People’s Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming, 650032, Yunnan Province, China.
推荐引用方式(GB/T 7714)：
Song Jianlin,Xu Jianbiao,Guo Jianhui,et al.The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.[J].ACTA HISTOCHEMICA.2021,123(6):doi:10.1016/j.acthis.2021.151769.
APA：
Song Jianlin,Xu Jianbiao,Guo Jianhui,Shang Yun,Wang Junyu&Wang Tongmin.(2021).The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy..ACTA HISTOCHEMICA,123,(6)
MLA：
Song Jianlin,et al."The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.".ACTA HISTOCHEMICA 123..6(2021)

资源点击量：82473 今日访问量：0 总访问量：681 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号